EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31

Edwards Lifesciences Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$87.22+0.62 (+0.72%)

Close on Oct 19, 2026

Market cap: $50.38B
P/E (TTM): 50.1
Dividend yield: –

Edwards Lifesciences Corp income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Revenue	6,068	5,440	5,010	4,464	5,233	4,386	4,348	3,723	3,435	2,964	2,494	2,323	2,046	1,900	1,679	1,447	1,321	1,238
Cost of Revenue	1,334	1,118	978	724	1,249	1,081	1,114	939	875	797	617	626	517	491	490	408	399	420
Gross Profit	4,733	4,322	4,032	3,740	3,984	3,306	3,234	2,783	2,560	2,166	1,877	1,697	1,529	1,409	1,189	1,039	922	818
Research & Development	1,079	1,053	963	844	903	761	753	622	553	442	383	347	323	291	246	204	176	139
Selling, General & Admin	2,085	1,789	1,583	1,358	1,494	1,228	1,242	1,089	991	905	851	858	733	697	642	550	509	481
Operating Income	1,264	1,379	1,309	1,498	1,690	898	1,147	748	1,089	751	–	–	–	–	–	–	–	–
Interest Expense	20	20	18	19	18	16	21	30	23	19	17	17	9.80	4.40	3.10	2.40	2.70	7.20
Interest & Investment Income	169	120	67	36	17	23	32	32	20	11	7.90	6.40	4.60	4.80	3.40	0.90	1.60	6.10
Income from Equity Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	1.80	0.70	1.50	-0.80	–
Other Non-Operating Income	8.70	169	64	21	13	12	8.20	4.00	-1.40	-4.90	-4.00	-7.70	–	–	4.80	8.10	3.70	-7.70
Merger & Restructuring Charges	13	33	0	61	–	–	–	–	–	–	0	0	10	9.00	5.50	–	–	–
Asset Impairment Charges	187	0	0	55	4.00	0	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	5.20	-0.10	-52	37	21	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	34	3,348	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Legal Settlements	-325	-40	-204	-16	-21	-405	-33	-214	73	-33	-7.00	3.70	0	–	–	–	–	–
Pretax Income	1,273	1,548	1,372	1,520	1,702	917	1,167	761	1,035	738	622	1,144	511	388	284	268	304	164
Income Tax Expense	217	152	152	196	199	93	120	39	451	168	128	333	122	97	47	50	75	36
Income from Continuing Operations	1,060	1,401	1,223	1,324	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Discontinued Operations	13	2,774	179	198	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	1,069	4,170	1,399	1,522	1,503	–	–	–	–	–	–	–	–	–	–	218	229	129
Minority Interest in Earnings	-4.10	-4.90	-3.00	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	1,074	4,175	1,402	1,522	1,503	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income to Common	–	–	1,402	1,522	1,503	823	1,047	722	584	570	495	811	389	292	237	218	229	131
EPS (Basic)(per share)	1.84	6.98	2.31	2.46	2.41	1.32	1.68	1.15	0.92	0.89	0.77	1.27	0.58	0.42	0.35	0.32	0.34	0.19
EPS (Diluted)(per share)	1.83	6.97	2.30	2.44	2.38	1.30	1.64	1.13	0.90	0.87	0.75	1.25	0.57	0.41	0.33	0.31	0.33	0.18
Shares Outstanding (Basic, Weighted)(shares)	585	598	607	619	623	623	625	628	633	639	647	639	670	689	688	682	675	670
Shares Outstanding (Diluted, Weighted)(shares)	586	599	609	624	631	632	637	641	648	653	661	651	683	710	716	715	705	715
EBITDA	1,421	1,534	1,454	1,638	1,825	1,005	1,236	826	1,171	822	–	–	–	–	–	–	–	–
Net Interest Income	-20	-20	-18	–	–	–	–	-30	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 77.8%
Operating margin: 22.3%
Net margin: 15.4%
Return on equity, FY2025: 10.6%

Financial strength

Current ratio: 4.52
Debt to equity: 0.06
Debt to assets: 4.3%
Cash to current liabilities: 192.8%

Valuation

P/E ratio: 50.1
Price to sales: 7.74
Price to book: 4.74
Dividend yield: –